Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-Outcomes tirzepatide in adults with metabolic dysfunction-associated steatotic liver disease
NL-OMON61112Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Eli Lilly and Company. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON61112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61112.